Keyword: Axonics Modulation Technologies
Axonics Modulation Technologies has received FDA approval for its rechargeable neuromodulation implant to treat bowel dysfunction.
Axonics Modulation Technologies has pulled in a meaty IPO as it looks to compete with medical technology major Medtronic.
The financing comes as Axonics closes in on the end of a clinical trial that will set it up to market the device in the U.S.
Genomics, bioelectronics and artificial intelligence are clear themes among FierceMedTech's 2017 Fierce 15 companies.
Axonics Modulation Technologies' approach is based on a technique known as sacral neuromodulation, which treats overactive bladder by delivering electrical stimulation to the sacral nerve, helping to correct erroneous messages sent between the bladder and the brain.
When we were compiling this year’s crop of Fierce 15 companies, some clear themes stood out. Genomics. Bioelectronics. Artificial intelligence. But while multiple companies are working to improve the use of these technologies, there runs a deeper current: making care more accessible.
Axonics Modulation Technologies raised $20.5 million in the second closing of its series C financing.
Axonics Modulation Technologies raised $14.5 million, which will bankroll a pivotal study of its neuromodulation implant for overactive bladder.